Prostanoids in the pathophysiology of human coronary artery

G Ozen1, X Norel2

  • 1INSERM U1148, CHU X. Bichat, 46 rue H. Huchard, 75018 Paris, France; Faculty of Pharmacy, Department of Pharmacology, Istanbul University, Istanbul, Turkey.

Insights

Prostanoids significantly impact human coronary artery function, influencing vascular tone and disease development. Prostacyclin offers benefits, while thromboxane A2 has adverse effects, highlighting their critical roles in heart health.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Medicine
  • Endocrinology

Background:

  • Coronary artery disease (CAD) is a major global health concern.
  • Prostanoids play crucial roles in regulating human coronary artery physiology and pathophysiology.
  • Understanding prostanoid involvement is key to addressing CAD.

Purpose of the Study:

  • To review prostanoid production and receptor expression in the human coronary artery.
  • To explore the interplay between sex hormones and prostanoids in CAD.
  • To elucidate the specific roles of various prostanoids in coronary vascular functions.

Main Methods:

  • Literature review of studies on human coronary artery preparations.
  • Analysis of data on prostanoid and receptor expression in health and disease.
  • Examination of experimental evidence regarding prostanoid effects.

Main Results:

  • Prostacyclin (PGI2) demonstrates vasodilatory and angiogenic properties.
  • Thromboxane A2 (TxA2) exhibits opposing, detrimental effects.
  • Sex hormones modulate prostanoid activity in coronary arteries.

Conclusions:

  • Prostanoids are vital mediators of coronary homeostasis.
  • Further research is needed on PGE2, PGD2, and PGF2α roles.
  • Therapeutic strategies targeting prostanoids may benefit cardiovascular health.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
838
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
352
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K